Holen Sie sich die Stockscreener-App
3.37
7.67%
0.24
Handel nachbörslich:
3.35
-0.02
-0.59%
Schlusskurs vom Vortag:
$3.13
Offen:
$3.13
24-Stunden-Volumen:
3.44M
Relative Volume:
0.71
Marktkapitalisierung:
$359.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-258.08M
KGV:
-1.2255
EPS:
-2.75
Netto-Cashflow:
$-202.32M
1W Leistung:
+19.93%
1M Leistung:
+24.81%
6M Leistung:
-67.84%
1J Leistung:
-86.00%
1-Tages-Spanne:
$3.13
$3.41
1-Wochen-Bereich:
$2.7501
$3.52
52-Wochen-Spanne:
$2.19
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Vergleichen Sie RCKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.37 | 302.74M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-30 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-05-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-28 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | Herabstufung | Needham | Buy → Hold |
| 2025-05-27 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-30 | Eingeleitet | Wedbush | Outperform |
| 2024-12-18 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-11-01 | Eingeleitet | BTIG Research | Buy |
| 2022-07-08 | Eingeleitet | Raymond James | Outperform |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2021-02-18 | Eingeleitet | Needham | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
| 2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - StreetInsider
Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. (RCKT) Shareholders of Class Action Lawsuit and August 11, 2025 Deadline - Barchart.com
Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop - TradingView
ROSEN, A TOP RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - GlobeNewswire Inc.
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class ActionHagens Berman - TradingView
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
What drives Rocket Pharmaceuticals Inc. Equity Warrant stock priceTremendous growth potential - jammulinksnews.com
Rocket Pharmaceuticals Inc. Equity Warrant Stock Analysis and ForecastExceptional ROI - jammulinksnews.com
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join - GlobeNewswire
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER - GlobeNewswire
What analysts say about Rocket Pharmaceuticals Inc. Equity Warrant stockExceptional growth trajectory - Autocar Professional
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Rocket Pharmaceuticals Inc (RCKT) Stock: Navigating a Year of Stock Volatility - investchronicle.com
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Is Rocket Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky to Join Class Action Before August 11, 2025 - ACCESS Newswire
2025-07-20 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky to Join Class Action Before August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse
What analysts say about Rocket Pharmaceuticals Inc. stockRapid-fire capital growth - jammulinksnews.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
2025-07-20 | RCKT LAWSUIT ALERT: Levi & Korsinsky Notifies Rocket Pharmaceuticals, Inc. InvestorsLead Plaintiff Deadline August 11, 2025 | NDAQ:RCKT | Press Release - Stockhouse
2025-07-19 | RCKT ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Rocket Pharmaceuticals, Inc.August 11, 2025 Deadline | NDAQ:RCKT | Press Release - Stockhouse
What drives Rocket Pharmaceuticals Inc. stock priceHigh-profit trading signals - Jammu Links News
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - StreetInsider
Rocket Pharmaceuticals Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
Is Rocket Pharmaceuticals Inc. Equity Warrant a good long term investmentUnrivaled growth potential - jammulinksnews.com
2025-07-18 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Join Class Action Before August 11, 2025Contact Levi & Korsinsky | NDAQ:RCKT | Press Release - Stockhouse
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - TradingView
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for InvestorsContact Levi & Korsinsky - cnhinews.com
(RCKT) Proactive Strategies - news.stocktradersdaily.com
2025-07-17 | RCKT LAWSUIT ALERT: Faruqi & Faruqi Notifies Rocket Pharmaceuticals Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:RCKT | Press Release - Stockhouse
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
FDA Clinical Hold on RP-A501 Trial Triggers Rocket - GlobeNewswire
Rocket Pharmaceuticals (RCKT) Surges on FDA RMAT Designation for Gene Therapy - GuruFocus
Rocket Pharma stock gains on FDA RMAT status (RCKT:NASDAQ) - Seeking Alpha
Rocket Pharmaceuticals stock surges after FDA grants key designation - Investing.com Australia
Rocket Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationRCKT - Barchart.com
Rocket Pharmaceuticals Receives FDA RMAT Designation - TipRanks
FDA grants RMAT designation to Rocket Pharma’s PKP2-ACM gene therapy - Investing.com Australia
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanc - GuruFocus
Rocket Pharmaceuticals (RCKT) Secures Key FDA Designation for Ge - GuruFocus
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy - Yahoo Finance
RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - The Malaysian Reserve
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):